There is an increasing understanding that monospecific antibodies are often insufficiently effective across all patients and/or indications. This has led to a growing interest in bispecific and multispecific modalities to target multiple signaling pathways and/or cell types. The goal of this round table will be to describe the current challenges in the discovery, generation, and characterization of bispecific and multispecific antibodies. We will furthermore discuss if the field is approaching any consensus on preferred formats and geometries, and how to arrive at the best molecule for a given application.
Monday, May 4, 14:30 - 15:00, room Rio, level 2
| Name | Position | Institution |
|---|---|---|
| William Roach | Sr Director of Technology Alliances | Adimab, LLC. |
Adimab is the industry's premier biologics discovery and engineering platform. Since 2007, we have established more than 140 therapeutic partnerships. To date, more than 90 programs have entered clinical trials, and 6 have reached the market. With a focus on developability, our platform delivers IgGs and HCAbs against multiple epitopes and with high specificity. Adimab utilizes synthetic diversity informed by machine learning and computational expertise as well as in vivo sources. Our technologies enable partners to generate and test hundreds of multispecifics and T cell engagers and is readily adaptable to other formats such as soluble TCRs.
